BIOTECH firm Cambridge Antibody Technology (CAT) has reported much improved annual results. CAT said a one-off payment resulting from its recent settlement with US giant Abbott Laboratories had increased turnover to £194m.
BIOTECH firm Cambridge Antibody Technology (CAT) has reported much improved annual results. CAT said a one-off payment resulting from its recent settlement with US giant Abbott Laboratories had increased turnover to £194m.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article